Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belrestotug
- Development stage
- Discontinued
- Lead developer
- iTeos Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Belrestotug is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that targets TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor expressed on T cells and natural killer cells. By antagonizing TIGIT, belrestotug is designed to enhance antitumor immune responses through multiple mechanisms including blocking the inhibitory TIGIT pathway, stimulating T lymphocyte activity via the CD226 pathway, and inducing antibody-dependent cellular cytotoxicity (ADCC) through FcγR engagement. Developed as an immunotherapy for cancer—primarily non-small cell lung cancer and head and neck squamous cell carcinoma—it was investigated in combination with other checkpoint inhibitors such as dostarlimab. The development program was discontinued in May 2025 after phase II/III trials failed to meet efficacy criteria[2][4][5][6].
- Brand names
- belrestotug
- Other names
- CLONE 31282CLONE31282CLONE-31282Immunoglobulin g1, anti-(human receptor tigit) (human monoclonal eos884448 .gamma.1-chain), disulfide with human monoclonal eos884448 .kappa.-chain, dimer
02
Targets
CD226 (DNAX accessory molecule 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on belrestotug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belrestotug.